June 8 (Reuters) – Johnson & Johnson said on Monday it will acquire biotech Firefly Bio for $1 billion in cash, as it looks to expand its cancer drug pipeline. (Reporting by Puyaan Singh in Bengaluru;
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)